A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America

201824 citationsJournal Articlebronze Open Access

Authors

Noopur Raje · Massachusetts General Hospital

G. David Roodman · Indiana University – Purdue University Indianapolis

Wolfgang Willenbacher · University Hospital Innsbruck

Kazuyuki Shimizu · Higashi Nagoya National Hospital

Ramón García‐Sánz · Complejo Hospitalario de Salamanca

Evangelos Terpos · National and Kapodistrian University of Athens

Lisa Kennedy

Abstract

Denosumab's efficacy in delaying or preventing SREs, potential to improve PFS, and lack of renal toxicity make it a cost-effective option for the prevention of SREs in MM compared with zoledronic acid.

Topics & Keywords

Multiple Myeloma Research and Treatments Bone health and treatments Oral and gingival health research

Publication Details

Published in: Journal of Medical Economics

Volume 21, Issue 5, pp. 525-536

DOI: 10.1080/13696998.2018.1445634

Field-Weighted Citation Impact: 2.45

Command Palette

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America

Authors

Abstract

Topics & Keywords

Publication Details